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Abstract
Alterations in function of the neurotrophin BDNF are associated with neurodegeneration, cognitive decline, and psychiatric
disorders. BDNF promotes axonal outgrowth and branching, regulates dendritic tree morphology and is important for
axonal regeneration after injury, responses that largely result from activation of its tyrosine kinase receptor TrkB. Although
intracellular neurotrophin (NT) signaling presumably reflects the combined action of kinases and phosphatases, little is
known about the contributions of the latter to TrkB regulation. The issue is complicated by the fact that phosphatases
belong to multiple independently evolved families, which are rarely studied together. We undertook a loss-of-function RNA-
interference-based screen of virtually all known (254) human phosphatases to understand their function in BDNF/TrkB-
mediated neurite outgrowth in differentiated SH-SY5Y cells. This approach identified phosphatases from diverse families,
which either positively or negatively modulate BDNF-TrkB-mediated neurite outgrowth, and most of which have little or no
previously established function related to NT signaling. ‘‘Classical’’ protein tyrosine phosphatases (PTPs) accounted for 13%
of the candidate regulatory phosphatases. The top classical PTP identified as a negative regulator of BDNF-TrkB-mediated
neurite outgrowth was PTPN12 (also called PTP-PEST). Validation and follow-up studies showed that endogenous PTPN12
antagonizes tyrosine phosphorylation of TrkB itself, and the downstream activation of ERK1/2. We also found PTPN12 to
negatively regulate phosphorylation of p130cas and FAK, proteins with previously described functions related to cell
motility and growth cone behavior. Our data provide the first comprehensive survey of phosphatase function in NT
signaling and neurite outgrowth. They reveal the complexity of phosphatase control, with several evolutionarily unrelated
phosphatase families cooperating to affect this biological response, and hence the relevance of considering all phosphatase
families when mining for potentially druggable targets.
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Introduction
During development, neurons extend neurites in response to
limited amounts of soluble or insoluble signals [1]. One of the
neurites will eventually become the axon and extend for a long
way to reach its target, while the remaining neurites will become
dendrites [2]. Axon elongation depends on the structure and
dynamics of actin filaments and microtubules within the growth
cone, which is strictly regulated by intracellular signaling cascades
in response to extracellular stimuli including growth factors, such
as neurotrophins (NTs) and extracellular matrix [1,3,4].
NTs are a major group of neurotrophic factors, which regulate
numerous neuronal functions during development, in the adult
state and in response to injury, such as neuronal survival and
death, cell migration, axon growth, synaptogenesis, neuronal
transmission and synaptic plasticity [1,5–7]. Members of the NT
family include nerve-growth factor (NGF), brain-derived neuro-
trophic factor (BDNF), NT-3 and NT-4/5. NTs bind to and signal
through two types of receptors: tropomyosin-related kinase (Trk)
receptors (NGF/TrkA), (BDNF and NT4-5/TrkB) and (NT-3/
TrkC) [1]; and the non-kinase p75 neurotrophin receptor
(p75NTR). Among the NTs, BDNF is enriched in the central
nervous system (CNS) [6] as is its receptor, TrkB. BDNF promotes
axon elongation and branching in vitro [8–10] and in vivo [9], and
in addition regulates dendrite tree morphology including primary
dendrite formation, dendrite branching and numbers of dendritic
spines [9,11]. Trk receptors are prototypical receptor-tyrosine
kinases, which upon ligand-induced dimerization autophosphor-
ylate tyrosine residues in their kinase domains as part of the
activation process. Phosphorylated tyrosine residues of activated
Trk receptors also function as docking sites for enzymes and
scaffold proteins leading to activation of the downstream signaling
pathways Ras-Raf-MEK-MAPK, PI3K-Akt and PLC-c1-PKC
[1,12]. In relation to BDNF-TrkB signaling the first two have been
associated with neuronal differentiation, neurite outgrowth and
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neuronal survival [1,13], while the PLC-c1-PKC pathway rather is
involved in synaptic plasticity [14].
Importantly, TrkB activation can also occur in response to non-
NT ligands such as glucocorticoids and adenosine as a
consequence of engagement of heterologous receptors, a process
known as transactivation [15,16]. Furthermore, engagement of
p75NTR by NTs can either enhance or suppress Trk signalling,
depending on the cellular context [17] and the degree of
processing of the pro-form; engagement of a supramolecular
receptor complex composed of TrkB, p75NTR and sortilin is
reported to mediate apoptosis [5,18,19].
NTs also play important roles in the diseased and recovering
nervous system. A common polymorphism in the human BNDF
gene is genetically associated with risk of various psychiatric
disorders [20]. As BDNF is a crucial modulator of synaptic
plasticity, its proper function is of relevance for cognitive functions
[21,22]. Moreover, neurodegenerative conditions such as Alzhei-
mer’s disease, Parkinson’s disease and Huntington’s disease are
correlated with decreased levels of BDNF and are associated with
a loss of synaptic connectivity and axonal demise [23,24]. The
BDNF-TrkB system also has a crucial role during nerve
regeneration, as demonstrated in experiments where neutralizing
antibodies to BDNF applied to animals with nerve lesion impede
axonal outgrowth [25], or where mice heterozygous for the TrkB
receptor show diminished axonal regeneration compared to wild-
type animals following nerve transection [26]. In spite of their
theoretical potential, NTs as therapeutic agents have had limited
success due to poor pharmacokinetics [27] and severe side-effects
[28], and thus treatment strategies improving cell intrinsic
mechanisms of axon elongation and regeneration would be
beneficial. Another recent strategy is the development of BDNF
mimetics specifically enhancing TrkB signaling, which have
showed promising results in rodent neurodegenerative models
[29].
Intracellular signaling cascades depend on dynamic phosphor-
ylation events that are tightly controlled by both kinases and
phosphatases. The ability of non-specific protein tyrosine phos-
phatases (PTP) inhibitors to activate Trk signaling and promote
neuronal outgrowth and survival in vitro [30,31] and neuroprotec-
tion in vivo [32] points to a role for PTPs in regulation of Trk
signaling. In accordance, RPTPf (PTPRZ1) and RPTPs (PTPRS)
can dephosphorylate TrkA and suppress NGF-induced neurite
outgrowth in PC12 cells and sensory neurons, respectively [33,34].
Conversely, the RPTP LAR (PTPRF) augments TrkB-mediated
signaling in hippocampal neurons through a mechanism involving
dephosphorylation of Src and activation of TrkB [35]. Recently,
the dual-specific phosphatase MKP-1 (DUSP1) was found to be
required for BDNF-dependent axonal branching [36], emphasiz-
ing that phosphatases can have diverse functions in relation to Trk
signaling. While the role of a few phosphatases in relation to
neurite outgrowth and Trk signaling has been studied in detail, the
majority has not been investigated.
Advances in large scale RNA interference (RNAi) screen
techniques and complex phenotypic analysis have made it possible
to take a more comprehensive approach in understanding the
signaling events underlying specific cellular processes. In relation
to neurite outgrowth this was recently exploited in a genome-wide
screen using Drosophila primary neurons [37], and in two kinase
screens related to retinoic acid (RA)-induced neurite outgrowth in
SH-SY5Y neuroblastoma cells [38,39].
In the present study we screened a highly comprehensive set
(254 genes) of human genomic phosphatases for their potential to
regulate BDNF/TrkB-mediated neurite outgrowth in an in vitro
cell-based assay. We identified multiple phosphatases that either
negatively or positively modulate neurite outgrowth. Mechanistic
analysis of the negative modulation of neurite outgrowth by the
protein tyrosine phosphatase PTPN12 (also known as PTP-PEST)
showed that it acts as a negative regulator of tyrosine phosphor-
ylation not only of p130cas and FAK as previously reported in
other cells, but also of TrkB. Moreover, PTPN12 knockdown
enhanced ERK1/2 activity (which is important during TrkB-
mediated neurite outgrowth [1,13]) in a TrkB-dependent manner.
Results
Sequential Treatment with Retinoic Acid and BDNF in SH-
SY5Y Cells
To identify phosphatases that regulate BDNF-TrkB-mediated
neurite outgrowth we developed a functional siRNA-based screen
system using the human neuroblastoma cell line SH-SY5Y [40].
After sequential treatment with retinoic acid (RA) and brain-
derived neurotrophic factor BDNF SH-SY5Y cells faithfully mimic
properties of differentiated neuron-like cells, as indicated by cell
cycle withdrawal, dependence on BDNF, and expression of
multiple neuronal and neuronal polarity markers [41,42]. Treat-
ment of naive SH-SY5Y cells for 4–5 days with RA resulted in a
partly differentiated neuronal phenotype manifested by long
neuritic processes and growth inhibition (Figure 1A) [41,43]. RA
induces the expression of TrkB with maximum expression after 5
days, thus sensitizing the cells to BDNF treatment [41].
Application of BDNF in serum-free medium to cells pretreated
with RA for 5 days resulted in a burst of neurite outgrowth
(Figure 1A) and increased level of GAP43 (Figure S1). GAP43 is a
highly expressed protein within the neuronal growth cone that is
important for growth and guidance of neurites [2,44], and its level
correlates positively with differentiation and the amount of neurite
outgrowth [45,46]. Under these conditions in the presence of
BDNF cells can be maintained for more than 3 weeks without
signs of neurodegeneration [41], thus giving a unique possibility to
study BDNF-TrkB-mediated neuronal events such as neuronal
survival and neurite outgrowth in a defined medium environment.
Large-scale Loss of Function Screen of Human
Phosphatases Involved in Neurite Outgrowth
To be able to estimate neurite outgrowth in an unbiased
automatic manner in a high-throughput context we developed an
algorithm which reliably could measure neurite length of b-III-
Tubulin stained neurites across different neuronal densities and
BDNF concentrations (Figures 1B and C). Cells pre-treated with
RA responded to BDNF with neurite outgrowth in a dose-
dependent manner, reaching saturation at 50 ng/ml BDNF
(Figure 1C). We observed that this treatment induced neurites of
lengths largely ranging between 50–200 mm, which is in accor-
dance with what has been previously been published using these
cells [38].
To integrate the RA-BDNF system with high-throughput RNAi
protocols we established transfection conditions using siRNAs
targeting TrkB and Rho-associated, coiled-coil containing protein
kinase 1 (ROCK1), which are well-established positive or negative
modulators of neurite outgrowth, respectively [35,41,47]. With the
aim being to screen for phosphatases implicated in BDNF-TrkB
related signaling we designed an experimental setup wherein
siRNA transfection after 3 days of RA would result in knockdown
of target genes before BDNF addition (which occurs at day 5 of
RA treatment), but with minimal interference of the RA-
differentiation per se. Cells were then left to differentiate in a
non-saturating concentration of BDNF (10 ng/ml, ,0.35 nM) in
serum-free medium for 3 more days, which would allow for
Phosphatases Modulating Neurite Outgrowth
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identification of both positive and negative regulators of BDNF-
TrkB dependent neurite outgrowth (Figure 2A).
Under these conditions the transfection efficiency was more
than 97% (Figure S2). Efficient knockdown at the protein level of
both TrkB and ROCK1 was seen at the time of BDNF addition
and persisted throughout the BDNF treatment period (Figure 2B).
Silencing of TrkB resulted in clear inhibition of GAP43 induction
by BDNF (compared to cells transfected with a scrambled (SCR)
siRNA control) (Figure 2B, left blot), indicating that it was possible
to silence BDNF-TrkB signaling and to modulate downstream
biological responses using our protocol. Importantly, transfection
with siRNA targeting either ROCK1 or TrkB significantly
increased or decreased BDNF-induced neurite outgrowth, respec-
tively, compared to transfection with the SCR siRNA control
(Figures 2C and D). No sequence-independent off-target effects
(OTEs), potentially caused by introducing siRNAs into the cells
[48–50], were seen when testing 6 different SCR control siRNAs
in comparison to mock transfected or non-treated control cells at 3
different BDNF concentrations (Figure S3).
For the screens we designed a comprehensive library targeting
254 human phosphatases (including protein, lipid, and carbohy-
drate phosphatases). For each target gene, 3 different siRNAs
(Ambion) were transfected (separately). The full screen was
performed 3 independent times using different passages of the
Figure 1. Automatic quantification of neurite outgrowth in RA/BDNF differentiated SH-SY5Y cells. A) Phase-contrast pictures of SH-SY5Y
cells plated at low density (left picture) and cultured for 5 days with 10 mM RA (middle picture) followed by 3 days in 50 ng/ml (,2 nM) BDNF in
serum-free medium (right picture). Scale bar = 50 mm. B) Representative fluorescent pictures of SH-SY5Y cells stained with an anti-b-III-Tubulin
antibody and Hoechst 33342. Cells were treated as in A) but with either 0 ng/ml BDNF (upper panel) or 50 ng/ml BDNF (lower panel). The pictures
were acquired automatically using an IN Cell 1000 automated high throughput microscope with a Nikon 206objective. Cells are shown without (left
panel) or with (right panel) overlay of the neurite tracing program. Scale bar = 50 mm. C) BDNF-neurite length dose response curve at low or high cell
densities (13,000 or 16,000 cells/cm2, respectively). Cells were differentiated for 5 days in RA and 3 days without or with BDNF at various
concentrations (0–250 ng/ml), stained as in B), and evaluated for neurite outgrowth using the developed neurite outgrowth algorithm. Data are
shown as mean 6 S.E.M. of triplicates, and are representative of three individual experiments.
doi:10.1371/journal.pone.0065371.g001
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SH-SY5Y cells. The normalized activity values (neurite length/
cell) obtained for individual sequence-specific siRNAs were
averaged over the screens, generating one activity-value per
siRNA, which was used for subsequent statistical analysis. This
approach was undertaken to reduce random error, thus increasing
the sensitivity of the screen data [51]. Data were normally
distributed and calculated z-scores (standard deviation from
median screen activity) for all siRNAs are plotted in Figure 3A.
Analysis of Screen Data
The widespread use of high-throughput siRNA-based screens
has highlighted the unfortunate caveat of a high incidence of
sequence-dependent OTEs, resulting in false positive hits [52–54].
Figure 2. Set-up of siRNA-mediated loss-of-function phosphatase screen in differentiated SH-SY5Y cells. A) Assay outline for the
phosphatase screen. Cells were plated in RA for a total of 5 days. At day 3 cells were transfected for 8 h with 50 nM siRNA in the presence of RA. At
day five, 48 h post-transfection, cells were changed into serum-free medium with 10 ng/ml BDNF and left to differentiate for 3 more days. Then cells
were fixed and stained with an anti-b-III-Tubulin antibody and Hoechst 33342. Image acquisition and data analysis were carried out automatically (see
Materials and Methods). B) Using the set-up described, cells were transfected with scrambled (SCR) siRNA or siRNA targeting TrkB or ROCK1, treated
with 50 ng/ml BDNF and lysed on different days as indicated. Expression levels of TrkB, GAP43 and ROCK1 were evaluated using western blotting.
GAPDH or a-Tubulin was used as loading controls. Densitometric quantification of the relative protein expression levels is shown below the blots. C)
Cells transfected and treated and evaluated as described in A). SCR, TrkB or ROCK1 siRNAs were used. Data are shown as mean and S.E.M. of four
replicates and is representative of two independent experiments (***: p#0.001; using one-way ANOVA followed by Dunnett’s multiple comparison
test with SCR siRNA treated cells as a reference). D) Representative pictures of cells transfected with SCR, ROCK1 or TrkB specific siRNAs (day 8 of A).
Scale bar = 50 mm.
doi:10.1371/journal.pone.0065371.g002
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Conventional analysis methods are based on activity ranking
followed by an arbitrary threshold cut-off selection process, which
typically identifies hits with only very high activity. By contrast,
redundant siRNA (RSA) analysis [55] is an alternative probability-
based analysis approach, that takes into account the collective
activity of all siRNAs targeting a specific gene, thus strongly
reducing the chance of sequence-dependent OTEs [49,55]. The
method assigns a p-value to individual genes, which reflect the
Figure 3. Primary screen data. A) Neurite length after siRNA-mediated knockdown of 254 different human phosphatases. Activities of individual
siRNAs are plotted as a function of the standard deviation of the median screen activity (z-score) (with each value representing the average from
three independent screens). The blue dashed lines mark the ‘‘top 100 activity cut-off for either negative regulators (above zero) or positive regulators
(below zero) of neurite outgrowth, while orange dots represent ‘‘top 100 RSA hits (only the most potent siRNA for the particular gene is marked). B)
RSA hit list including genes with p#0.01 in the RSA analysis for either negative or positive regulators of neurite outgrowth. Critical rank indicates how
many of the three gene-specific siRNAs contributed to the gene p-value. Filled circles represent hits that have been validated in a separate sub-
screen, while open circles represent hits that could not be validated.
doi:10.1371/journal.pone.0065371.g003
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distribution of all the gene-specific siRNAs tested toward high (or
low) activity. This type of analysis thus identifies hits that are
distributed much deeper into the dataset than conventional
activity cut-off methods while simultaneously yielding significantly
better validation rates [55], which reflects a higher rate of
identification of true biological hits in the primary analysis. In our
dataset top 10 hits identified by RSA analysis also distributed
much deeper into the dataset (orange dots) compared to top 10
activity hits (blue line, Figure 3A).
Figure 3B lists hits with a p-value #0.01 in the RSA analysis for
either negative or positive regulators (extended hit lists for negative
and positive regulators can be found in Tables S1 and S2,
respectively). The NTRK2/TrkB and ROCK1 controls yielded p-
values of 1.4E-12 and 2.0E-06, respectively, indicating that the
screen performed well in both directions. These controls are not
included in the hit list of identified regulators, since their p-values
are not directly comparable to the tested genes due to their high
number and pre-validated function (see Supporting Materials and
Methods Document S1). However, three siRNAs targeting
NTRK2, were also included as perfectly comparable controls in
the pre-spotted siRNA plates from the manufacturer (Ambion),
and thus can be compared directly to the other siRNAs in the
library. In this case, we found that the RSA analysis placed
NTRK2/TrkB among the top 10 positive regulators of BDNF-
mediated outgrowth (p-value = 0.01), further supporting that the
screen behaved satisfactorily.
Validation
11 negative and 4 positive hits were selected for validation based
on criteria of interest and representation of the various phospha-
tase subgroups. We predominantly selected negative modulators
for validation and follow-up because their knockdown phenotype
is more likely to be biologically specific, and in view of a potential
interest as therapeutic targets.
The validation screen was performed essentially as for the main
screens (10 ng/ml BDNF), using siRNAs corresponding in
sequence to one of the three siRNAs in the main screen, but
purchased from another vendor (Sigma). 9/11 of the negative
regulators and 2/4 of the positive regulators tested were validated
resulting in an overall validation efficiency of 73% (Figure 4). The
knockdown efficiency of four randomly chosen hits, including both
validated and non-validated hits was tested by qPCR (Figure S4).
For all four genes specific siRNA treatment resulted in 50–75%
reduction in mRNA level, which indicates a reasonable knock-
down efficiency, and thus that lack of phenotypic validation did
not necessarily correlate with lack of mRNA knockdown (PTPN1;
Figure 4A).
Even though we purposely designed the screen to enrich for hits
affecting BDNF signaling we considered the possibility that some
hits would function in a BDNF- or TrkB-independent fashion. To
distinguish between BDNF-dependent and -independent hits we
performed further validation in absence of BDNF. Surprisingly,
we observed a significant effect of TrkB knockdown on neurite
outgrowth in the absence of BDNF (Figure S5A and B). This may
reflect an autocrine source of BDNF [56], spontaneous dimeriza-
tion of TrkB [57] or TrkB transactivation by other signals [58,59],
thus hampering assessment of hits in the absence of TrkB
signaling. At the same time, this observation underscores the
central contribution of TrkB signaling to outgrowth in our
screening assay. Among the negative regulators, knockdown of
some (ACYP1, PTPMT1 and TENC1) induced outgrowth even in
absence of BDNF (Figure S5A), suggesting that they are either
particularly important in the suppression of basal levels of TrkB
signaling, or act on a parallel pathway; by contrast, knockdown of
PTPN12 (and ENOPH1, DUSP12, PNKP, DOLPP1, LPPR4) did
not affect outgrowth in SH-SY5Y cells in the absence of BDNF.
Neither of the two validated positive regulators, PPM1J and
UBASH3B, significantly affected outgrowth in absence of BDNF
(Figure S5B), suggesting that either the BDNF-independent
window for decreasing outgrowth was too small, or that outgrowth
in absence of exogenous BDNF does not depend on these genes.
As opposed to the intermediate BDNF concentration used in the
primary screen we also tested how knockdown of the identified hits
would affect outgrowth in the presence of a saturating BDNF
concentration (50 ng/ml) (Figure S5C and D). Among the
negative regulators only PTPMT1 knockdown resulted in
increased outgrowth even at saturating BDNF concentration,
Figure 4. Validation of hits from the primary screen. Some of the
hits identified in the main screen (here defined as p,0.05) were tested
for validation in a sub-screen following the screen protocol described in
Figure 2A using newly purchased siRNAs from another vendor. UNC1 is
the scrambled siRNA control while ROCK1 or TrkB targeting siRNAs
served as biological controls. A) 11 negative regulators and B) 4 positive
regulators were included in the sub-screen. Negative and positive
regulators were screened on separate plates, which both included
controls. Normalization between plates was not performed, explaining
the slight variation in the control values between A) and B). Red and
green indicates negative and positive regulators respectively, and filled
and open bars represent validated and non-validated hits, respectively.
Data are shown as mean and S.E.M. of triplicates (*: p#0.05; **: p#0.01;
and ***: p#0.001; using one-way ANOVA followed by Dunnett’s
multiple comparison test with UNC1 as reference).
doi:10.1371/journal.pone.0065371.g004
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while others only suppressed outgrowth under modest BDNF
concentrations (PTPN12, DUSP12, LPPR4) (Figure S5C). Under
this condition loss of PPM1J but not UBASH3 significantly
decreased neurite length, indicating that loss of PPM1J function
cannot be rescued by higher BDNF concentration; by contrast
UBASH3B appeared to be most critical for outgrowth at
intermediate levels of BDNF (Figure S5D). These differential
interactions with BDNF stimulation reveal a functional classifica-
tion of protein phosphatases affecting neurite outgrowth.
Hits Identified in the Screen
Among the genes identified are members of all phosphatase
subgroups. ACYP1 is an acylphosphatase; ENOPH1 and PNKP
belong to the l–2-halo-acid dehalogenase (HAD) superfamily of
hydrolases; DOLPP1, LPPR4 and TENC1 are generally consid-
ered as lipid phosphatases, while PTPN12 is a classical tyrosine
phosphatase. DUSP12 is a member of the dual-specific phospha-
tase family, while PPM1J is a serine/threonine phosphatase of the
PPM family. Most of the genes identified have not previously been
associated with a neurite outgrowth phenotype and many have
been poorly characterized in the literature.
PTPN12 Phenotypic Validation Using TrkB-SH-SY5Y Cells
PTPN12, which we identified as a negative regulator of BDNF-
TrkB mediated neurite outgrowth (Figure 4A), is known to control
various aspects of cell motility in response to both extracellular
matrix (ECM) and growth factors in fibroblasts [60–63]. Recently,
PTPN12 was found to interact with and dephosphorylate the
RTKs EGFR and ErbB-2, thereby acting as a tumor suppressor in
breast cancer by suppressing MAPK signaling [64]. Moreover,
PTPN12 was found to interact with multiple RTKs such as
PDGFb, EGFR and c-Kit in HEK293 cells [65]. Furthermore,
PTPN12 negatively regulates insulin-induced MAPK signaling
through a direct interaction with the adaptor protein Shc, which
leads to dephosphorylation of ShcY317 [66]. A similar mechanism
for PTPN12 is reported in a B-cell line after BCR activation [67].
Strikingly, only a single study (on its negative regulatory role in
response to Ab-mediated neuronal dystrophy) has addressed the
role of PTPN12 in a neuronal context [68]. This knowledge gap
led us to examine PTPN12 function of in BDNF/TrkB-mediated
neurite outgrowth in greater detail.
For these studies we generated stable cell lines expressing a
shRNAmir targeting PTPN12, or a non-silencing control, in SH-
SY5Y cells that already stably express TrkB (TrkB-SH-SY5Y) [69]
(Figure 5A). This TrkB-expressing cellular context was used to
circumvent any effects of PTPN12 knockdown on differentiation
with RA, thus securing that we only examined its effects on TrkB
signaling. The TrkB-SH-SY5Y cells expressed levels of TrkB
approximately similar to whole brain tissue and cultured cerebellar
granule neurons (Figure S6A), which indicates a physiological
relevance. The cells also responded to BDNF with neurite-like
outgrowth and increased GAP43 expression (Figures S6B and C,
respectively). However, BDNF-mediated outgrowth in TrkB-SH-
SY5Y cells appeared morphologically distinct from that in RA-
pretreated cells (compare Figure 1A with Figure S6B) indicating a
contribution of RA-induced differentiation prior to BDNF
stimulation. Nevertheless, we found that also in TrkB-SH-SY5Y
cells not exposed to RA, PTPN12 knockdown increased the
number of cells with neurite-like protrusions (a comparable but
more sensitive parameter in TrkB-SH-SY5Y cells than mean
neurite length/cell) in response to BDNF (Figure 5B). These
morphological data were further strengthened by increased levels
of GAP43 in the PTPN12 knockdown cells compared to controls
(Figures 5C and D). We note that, as opposed to SH-SY5Y cells
(Figure S5B), PTPN12 knockdown affected outgrowth in TrkB-
SH-SY5Y cells even in absence of BDNF. However this does not
exclude regulation of TrkB signaling by BDNF, particularly since
the higher TrkB levels in TrkB-SH-SY5Y cells (Figure S6A) may
favor ligand-independent TrkB signaling [34,57]. We conclude
that PTPN12 knockdown affects neurite outgrowth independently
of a RA-induced differentiation response, and that TrkB-SH-
SY5Y cells can be used to identify PTPN12 substrates that may be
important for outgrowth, including potentially TrkB itself.
PTPN12 Knockdown Causes Increased Phosphorylation
of p130cas and FAK
PTPN12, an intracellular PTP, acts on many substrates related
to motility in response to growth factors or ECM, such as Shc,
p130cas, FAK, Csk, paxillin and PSTPIP1 [70–72]. We first
compared the pattern of tyrosine phosphorylation between
PTPN12 knockdown and control cells in the absence of BDNF.
As shown in Figure 6A PTPN12 knockdown was associated with
increased phosphotyrosine (pY) levels. Most prominent were bands
with apparent MW ,130 kDa, corresponding in size to the well-
established PTPN12 substrates p130cas and FAK
(MW,125 kDa). Indeed, through immunoprecipitation experi-
ments we showed that both p130cas and FAK are hyperpho-
sphorylated on tyrosine residues in PTPN12 knockdown cells
(Figure 6B) and thus most likely are substrates for PTPN12 in
TrkB-SH-SY5Y cells.
PTPN12 Modulates TrkB Signaling
We wished to test the hypothesis that phosphorylation of TrkB
itself would be affected by knockdown of PTPN12 in TrkB-SH-
SY5Y cells. Recent data, in tumor contexts, have shown that
PTPN12 can dephosphorylate receptor tyrosine kinases [64].
Indeed, a phospho-specific antibody against pY816 in TrkB [73]
revealed increased tyrosine phosphorylation of this residue
following PTPN12 knockdown, in absence of exogenous BDNF,
or in presence of low BDNF concentrations, (Figure 7A).
Quantification of pY816 in TrkB relative to total TrkB levels
showed a ,2-fold increase in pY TrkB in cells lacking PTPN12 in
the absence of BDNF, and ,1.5-fold increase in the presence of
1 ng/ml BDNF (Figure 7A).
The increase in TrkB activation following PTPN12 knockdown
was accompanied by increased phosphorylation of the MAPK
ERK1/2 (Figure 7A), in accordance with ERK1/2, a regulator of
differentiation and neurite outgrowth, being a downstream
mediator of TrkB signaling [1,5,13]; PTPN12 knockdown also
boosted Akt phosphorylation (Fig. 7A).
ERK1/2 can be activated through changes in FAK and
p130cas activity [74]. To elucidate the events upstream of ERK1/
2 phosphorylation we treated cells under basal conditions with the
Trk inhibitor K252a and quantified the ensuing effect on pERK1/
2 levels (Figures 7B). K252a treatment reduced the increase in
pERK1/2 phosphorylation caused by PTPN12 knockdown. This
suggests (subject to the caveat of K252a specificity) that the pERK
phenotype partly can be explained by changes related to TrkB, but
also partly by TrkB-independent events, such as increased p130cas
and FAK activities.
To ask whether PTPN12 also controlled TrkB activation state
in primary neurons, we subjected cultured mouse hippocampal
neurons to lentiviral knockdown of endogenous PTPN12. Anal-
ogously to our observations in TrkB-SH-SY5Y cells, stable
knockdown of Ptpn12 (Figure 8A) resulted in a statistically
significant increase in TrkB phosphorylation on residue Y816 in
response to exposure to BDNF (Figure 8B), confirming that
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Ptpn12 negatively regulates TrkB phosphorylation in cultured
mouse primary neurons.
Discussion
Development of an Automated siRNA Screening Strategy
in Neuronally Differentiated SH-SY5Y Cells
We developed a robust high-throughput siRNA-based screening
protocol in differentiated human neuron-like SH-SY5Y cells to
identify regulators of BDNF-TrkB signaling pathway controlling
neurite outgrowth. Sequential treatment of SH-SY5Y cells with
RA and BDNF creates a homogenous population of mature
neuron-like cells that are withdrawn from the cell cycle, express
many markers of mature neurons (such as GAP43, MAP2, NeuN,
synaptophysin and TrkB), have neuronal marker enzyme activity
(tyrosine- and dopamine-b-hydroxylases), exhibit carbachol-
evoked noradrenaline release, and are dependent on NTs for
survival [41,42]. Accordingly, they are a reasonable alternative to
primary neurons when it comes to large-scale RNAi-based
screening methods, since they are more easily transfected to
induce RNAi-mediated gene silencing than primary neurons [75].
Signaling events are dependent on the combined and regulated
effects of both kinases and phosphatases. A recent study using
over-expression of 450 selected kinases and phosphatases in
hippocampal neurons revealed that only a few of the hits identified
as enhancers of neurite outgrowth on laminin also enhanced
outgrowth on poly-lysine [76], suggesting that the signaling
pathways underlying neurite outgrowth are particular to the
experimental conditions used. This is further underscored by the
observation that, among the three reported large-scale siRNA
screens investigating the function of kinases and/or phosphatases
in relation to neurite outgrowth/migration, not a single protein
consistently promoted or suppressed neurite outgrowth/migration
[37,38,77] (compared in [76]). It is therefore crucial to perform
screens that are carefully designed to answer particular biological
questions. Our present study differed from all of the above in
focusing on identification of phosphatases that regulate BDNF-
mediated neurite outgrowth in fully differentiated neuronal cells.
To our knowledge this is the first large-scale screen addressing
signaling events directly related to NT-mediated neurite out-
growth.
Neurite Outgrowth is Modulated by a Large Number of
Diverse Phosphatases
We did not find any specific phosphatase gene families that were
particularly enriched among the top positive or negative regulators
identified by the primary screen. This is in accordance with
previous observations that a diverse range of proteins are involved
in regulation of neurite outgrowth, both across functional gene
Figure 5. PTPN12 decreases neurite-like outgrowth in TrkB-SH-SY5Y cells. A) Western blot analysis of PTPN12 expression level in TrkB-SH-
SY5Y cells stably expressing a pGIPZ shRNAmir non-targeting PTPN12 (PTPN12 kd) or the non-silencing control. a-Tubulin is used as reference. B)
Neurite-like outgrowth in PTPN12 kd cells compared to the control. Cells were seeded at low density and grown for 24 h before stimulation with
BDNF as indicated for 3 days in serum-free medium. Cells were then stained with a b-III-Tubulin antibody and Hoechst 33342 and pictures were
acquired and analyzed automatically. Data shown are mean and S.E.M. of triplicates and are representative of two independent experiments.
Statistical analysis was performed using Student’s t-test comparing PTPN12 kd and control cells for each BDNF concentration (**: p#0.01; ***:
p#0.001). C) Western blot analysis of cells treated as in B) for GAP43 expression using Vinculin as loading reference. D) Densitometric quantification
of the results in C).
doi:10.1371/journal.pone.0065371.g005
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classes [37] and among kinase or phosphatase families [76,77].
Most of the validated negative regulatory phosphatases (Figure 4),
such as the lipid phosphatase ACYP1, the aspartate-based (HAD-
family) phosphatase ENOPH1, and the tyrosine phosphatases
PTPMT1 and PTPN12 are poorly characterized, in terms of
association with neurite outgrowth. It will be of interest to
investigate their relation to the classical BDNF-TrkB signaling
pathway. Other negative regulators, such as TENC1, have better-
known activities that could point to mechanisms of regulation of
BDNF-TrkB signaling. For TENC1 these include decreasing
plasma membrane phosphatidylinositol 3,4,5-trisphosphate levels
[78], inhibition of Akt signal transduction [79,80], activation of the
growth cone collapse promoting protein Rho [81] and direct
interaction with a RTK [82]. The strongest identified and
validated positive regulator of BDNF-TrkB mediated neurite
outgrowth, PPM1J, belongs to the PP2C phosphatase subgroup
[83,84] and is also very poorly characterized. Thus, further studies
of its regulatory function in NT signaling are warranted.
Single gene studies have previously implicated PTPs in the
control of BDNF responses, e.g. LAR (PTPRF) as a positive
regulator of BDNF neurotrophic activity in hippocampal neurons
[35], and MKP-1 (DUSP1) in BDNF-induced axon branching in
cortical neurons [36]. The phosphatases RPTPf (PTPRZ1) and
RPTPs (PTPRS) can counteract NGF/TrkA-induced outgrowth
in cell types other than SH-SY5Y [33,34]. Among these PTPs, our
screen only detects LAR (PTPRF) (as a negative regulator of
outgrowth; Table S1). Differences in read-out and cell type, and/
or insufficient sensitivity of our siRNA-based protocol may explain
the lack of detection by our screen of the above PTPs previously
implicated in control of neurotrophin-induced neurite outgrowth.
PTPN12 as a Negative Regulator of Neurite Outgrowth
Among the so-called ‘‘canonical’’ protein tyrosine phosphatases
we found PTPN12 to be the most effective negative regulator of
BDNF-TrkB mediated outgrowth in our screen. We selected this
gene for further mechanistic follow-up, given the almost complete
absence of studies in a neuronal context on this otherwise well-
studied PTP. PTPN12 consists of an N-terminal catalytic domain
and a C-terminal domain containing a proline-rich region to
which many interaction partners bind (such as p130cas, FAK,
paxillin, Grb2 and Csk), a NxPH binding site for Shc, and a CTH
domain that interacts with PSTPIP [72].
PTPN12 has been previously linked to membrane protrusion,
focal adhesion turnover and cell migration [60–63,68,85] through
its effect on GEFs and GAPs for the small Rho GTPases Rac1 and
RhoA, respectively [63,86]. Neurite extension requires reorgani-
zation of the growth cone cytoskeleton and is largely controlled by
Rho family GTPases [1,87]. Rac1 and RhoA have antagonistic
effects on this process, in that Rac1 promotes neurite outgrowth
and RhoA triggers growth cone collapse [87,88]. Thus, PTPN12
might partly control BDNF-TrkB mediated neurite outgrowth
through regulation of Rac1 and RhoA activity. Indeed, several
GEFs for Rac1 are recruited to activated Trk receptors in neurons,
resulting in activation of Rac1 and neurite outgrowth [89,90].
We found that PTPN12 knockdown led to an increase in
tyrosine phosphorylation of both p130cas and FAK in TrkB-SH-
SY5Y cells. This is in accordance with reports of hyperpho-
sphorylated p130cas and FAK in Ptpn122/2 fibroblasts [60], and
hyperphosphorylated p130cas in Ptpn122/2 embryos [85]. The
role of p130cas in migration depends largely on its tyrosine
phosphorylation by FAK and Src family kinases (SFKs) after
Figure 6. PTPN12 changes the phosphotyrosine profile in TrkB-SH-SY5Y cells. A) Total phosphotyrosine pY levels (4G10 antibody) were
revealed by western blotting in lysates from control or PTPN12 kd cells cultured for 24 h and starved for 4 h prior to lysis (basal condition). Vinculin
served as loading reference. B) Lysates prepared from cells as in A) were immunoprecipitated (IP) using p130cas or FAK antibodies and blotted for
total pY levels (4G10 antibody). Total p130cas and FAK levels were used as the respective references. Densitometric quantification of the tyrosine
phosphorylation level of p130cas and FAK (4G10), compared to total p130cas and FAK levels, is shown as mean and S.E.M. of three and five
independent experiments respectively, with values normalized to the control. Statistical analysis was performed using Student’s paired t-test (*:
p#0.05).
doi:10.1371/journal.pone.0065371.g006
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growth factor receptor or integrin activation (by BDNF and
collagen, respectively, in our assays) and assembly of the p130cas-
Crk-DOCK180 scaffold, which drives localized Rac1 and MAPK
activation [70,74,91]. Hyperphosphorylation of p130cas following
PTPN12 knockdown could thus be caused indirectly through
increased FAK activity, which could also contribute to the increase
in pERK1/2 (Figure 7) known to be important for neurite
outgrowth together with Rac1 activation [1].
Importantly, we have also shown that the TrkB receptor for
BDNF becomes hyperphosphorylated on Y816 in absence of
PTPN12 in TrkB-SH-SY5Y cells as well as in primary
hippocampal neurons, pointing to a role for PTPN12 in
controlling TrkB receptor proximal signaling events. This effect
Figure 7. PTPN12 modulates TrkB signaling in TrkB-SH-SY5Y cells. A) Western blot analyses for pY816-TrkB, TrkB, pERK1/2, pAKT and
Vinculin levels in control and PTPN12 kd cells cultured for 24 h, starved for 4 h and stimulated for 5 min with 0, 1 or 10 ng/ml BDNF. Graphs show
densitometric quantifications of pY816-TrkB compared to total TrkB, and pERK1/2 and pAKT compared to total Vinculin, for cells in absence of BDNF
(basal level) or with 1 ng/ml BDNF (mean and S.E.M. of three, seven, and four independent experiments respectively). PTPN12 kd values were
normalized to the level of the control for each BDNF concentration. NB: p-value= 0.076 for comparison of pAKT between control and PTPN12 kd both
at 0 ng/ml BDNF. B) PTPN12 kd and control cells cultured as in A) in the absence of BDNF 6 K252a were analyzed for pERK1/2 levels using GAPDH as
a reference. Respective densitometric quantifications are shown as mean and S.E.M. of three independent experiments; PTPN12 kd is normalized to
the level of the control in the absence or presence of K252a. Statistical analyses were performed using Student’s paired t-test comparing control and
Ptpn12 kd, except where otherwise specified (*: p#0.05; ***: p#0.005). NB: p-value= 0.060 for comparison of pERK between control and PTPN12 kd
both treated with K252.
doi:10.1371/journal.pone.0065371.g007
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of PTPN12 on TrkB activation predominantly appears at non-
saturating levels of exogenous BDNF. One possibility is that
PTPN12 directly dephosphorylates TrkB, similarly to the ability of
RPTPf (PTPRZ1) and RPTPs (PTPRS) to dephosphorylate
TrkA, and thereby attenuate NGF-induced ERK1/2 signaling
[33,34]. PTPN12 co-precipitates with several other RTKs [65]
and was recently shown to dephosphorylate EGFR and HER2 in
breast tumors, thereby inhibiting MAPK signaling [64]. PTPN12
knockdown in human mammary epithelial cells led to a two-fold
increase in RTK phosphorylation [64], which is in the same range
of our observations for TrkB after PTPN12 knockdown in TrkB-
SH-SY5Y cells (Figure 7) and in hippocampal neurons (Figure 8).
PTPN12 could be recruited to TrkB through its capacity to
interact with adaptors or scaffold proteins such as Grb2, Crk, and
Shc present at the activated TrkB receptor [1,72]. Alternatively,
PTPN12 might not directly dephosphorylate TrkB, but could
affect its phosphorylation indirectly, e.g. through its effects on
intermediate tyrosine kinases, such as members of the Src family
(which are known to regulate NT-independent transactivation of
Trk receptors [15,58,92,93]), or through FAK. Experiments with
PTPN12 substrate trapping mutants may help clarify these issues
[94]. Finally, the issue of possible effects of PTPN12 on the control
of phosphorylation of TrkA and TrkC will also need to be
considered.
Interestingly, PTPN12 knockdown does not affect neurite
outgrowth in absence of BDNF in SH-SY5Y cells (Figure S5),
but does so in (TrkB-overexpressing) TrkB-SH-SY5Y cells
(Figure 5B). This may indicate that PTPN12 might modulate
TrkB phosphorylation only when TrkB is itself activated (by ligand
in SH-SY5Y cells, or by overexpression in TrkB-SH-SY5Y cells);
mechanisms responsible could include altered TrkB or PTPN12
localization, or modulation of PTPN12 catalytic activity in
response to BDNF/TrkB activation.
The phosphorylated Y816 residue in TrkB acts as a PLCc
binding site, whereas phosphorylation of another residue, Y515, is
associated with Shc docking. The literature indicates that it is not
possible to cleanly assign ERK activation to one site: there appear
to be Y515/Shc-independent pathways to ERK activation, and
the Y816/PLC-c-binding site can contribute to ERK activation by
Trks [95,96]. We have also observed statistically significant effects
of PTPN12 knockdown on phosphorylation of the Y515 residue
(FN, VD, and JS, unpublished observations), a docking site for
Shc. Thus, a causal link between PTPN12 knockdown-induced
TrkB hyperphosphorylation and ERK hyperactivation seemed
plausible. To investigate the contribution of TrkB hyperpho-
sphorylation to the pERK1/2 activation associated with PTPN12
knockdown, we used the Trk inhibitor K252a. K252a treatment
reduced the PTPN12 knockdown-induced increase in pERK1/2
by only 50%, suggesting that ERK activation following PTPN12
knockdown is only partly due to TrkB hyperactivation. The
presence of hyperphosphorylated p130cas and FAK, associated
with increased integrin responsiveness, might account for the
remaining part of the elevated ERK phosphorylation following
PTPN12 knockdown (subject to the caveats associated with the use
of inhibitors). At any rate it may be exceedingly difficult, and of
limited utility, to try and further disentangle both processes, as
neuronal FAK and Src are integration points between growth
factor and integrin signaling, with activation of both pathways
having synergistic effects on neurite outgrowth [97,98].
Outlook
BDNF participates in regenerative processes [25,26], and
decreased BDNF function is associated with neurodegeneration,
cognitive decline, and psychiatric disorders [20–24]. Our study
reveals the extent of phosphatome regulation of BDNF respon-
siveness. Phosphatases that negatively control BDNF sensitivity
may have promise as pharmacological targets to potentiate the
effect of limiting amounts of endogenous factor. While the
diversity in surface structure properties among PTPs (including
e.g. the predicted presence of an accessible secondary non-
catalytic substrate-binding pocket in PTPN12 [99]) might augur
well for development of selective PTP inhibitors, and progress has
been made, substantial hurdles remain to be overcome [100,101].
Strikingly, while we identify PTPN12 as a novel negative
regulator of BDNF-receptor activity, we observe that such
‘‘classical’’ PTPs only play a limited role in phosphatase control
of this tyrosine kinase-mediated response (8/60 = 13% of the hits
under the p,0.01 significance mark). This prompts a compre-
hensive view of phosphatase control, with multiple categories of
evolutionarily unrelated phosphatase families having converged to
orchestrate a biological response [102,103]. Our study thus reveals
the breadth of the spectrum of target families that could potentially
be exploited to modulate BDNF signaling to therapeutic effect.
Figure 8. PTPTN12 knockdown in primary mouse hippocampal
neurons enhances tyrosine phosphorylation of TrkB. A) Western
blot analysis of PTPN12 expression in mouse hippocampal neurons
expressing a pLKO-shRNA targeting PTPN12 (PTPN12 kd) or a non-
silencing control. a-Tubulin is used as reference. Densitometric
quantification of PTPN12 expression is shown as mean and S.E.M. of
five independent experiments, and values are normalized to the level of
the non-silencing control. B) Western blot analysis of pY816-TrkB and
Trk levels in mouse hippocampal neurons expressing a pLKO-shRNA
targeting PTPN12 (PTPN12 kd) or a non-silencing control. The neurons
were cultured for 5 days and then stimulated for 5 min with 0 or 10 ng/
ml BDNF. Densitometric quantification of pY816-TrkB compared to total
Trk levels are shown as mean and S.E.M. of five independent
experiments, and values are normalized to the level of the control in
the absence of BDNF. Statistical analyses were performed using
Student’s paired t-test comparing control and Ptpn12 kd, except when
otherwise specified (*: p#0.05; ***: p#0.005).
doi:10.1371/journal.pone.0065371.g008
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Materials and Methods
Cell Culture, Differentiation, Stimulation and siRNA
Transfection of SH-SY5Y Cells
The SH-SY5Y neuroblastoma cell line was from S. Pa˚hlman
(Lund University, Malmø, Sweden). Cells were grown on dishes
pre-coated with 50 mg/ml of type I rat tail collagen in Minimum
Essential Medium (MEM, Gibco) supplemented with 2 mM L-
glutamine, 10% fetal bovine serum (FBS) (Gibco), penicillin (100
units/ml), and streptomycin (100 mg/ml) (pen-strep) (MEM
medium). For experiments, cells were seeded at low density
(13,000 cells/cm2) in medium additionally supplemented with
10 mM all-trans retinoic acid (RA) (Sigma) (RA medium). After 4–5
days, cells were washed twice in serum-free MEM medium and
incubated with BDNF (a gift from Regeneron Pharmaceuticals
Inc., Tarrytown, NY, USA) in serum-free MEM medium as
indicated. siRNA transfections were carried out after 3 days in RA
medium. Briefly, medium was changed into RA medium without
antibiotics, and a transfection mixture consisting of OptiMEM
(Invitrogen), siRNA (final concentration 50 nM) and Lipofecta-
mine 2000 (Invitrogen), prepared according to the manufacturer’s
instructions, was added. After 8 h, transfection medium was
replaced with fresh RA medium. A SH-SY5Y cell line expressing
full-length TrkB (TrkB-SH-SY5Y cells) was a kind gift from A.
Schramm (Essen, Germany) [69]. TrkB-SH-SY5Y cells were
grown on collagen-coated dishes in RPMI-1640 (Gibco) supple-
mented with 2 mM L-glutamine, 10% FBS, pen-strep (RPMI
medium) and geneticin (500 mg/ml). For experiments, cells were
plated for 24 h in RPMI medium, starved for 4 hours in serum-
free RPMI, and stimulated with BDNF in serum-free RPMI
medium as indicated. Trk inhibitor K252a (300 nM) (Sigma) was
applied as a 15 min pre-treatment and left in medium throughout
the experimental period. Cells were maintained at 37uC in a
humidified incubator containing 5% CO2.
Generation of Lentiviral Particles and Infection of TrkB-
SH-SY5Y Cells and Primary Hippocampal Neurons
A 2nd generation packaging system was used to produce virus.
5 mg transfer vector was co-transfected together with 10 mg
pMD2G (VSV-G, Addgene plasmid 12259) and 5 mg psPax2
(gag-pol, tat-rev; Addgene plasmid 12260), using calcium phos-
phate coprecipitation, into 2.66106 human embryonic kidney
293T cells (ATCC CRL-11268) seeded 24 h before transfection.
Supernatant containing viral particles was harvested 48 h post-
transfection.
To infect TrkB-SH-SY5Y cells we used GIPZ-based lentiviral
shRNAmir transfer vectors targeting human PTPN12 (sense:
CGAGTTAAATTGACATTAA) or the non-silencing control
(Open Biosystems). Unconcentrated supernatant containing viral
particles was used directly for infection. The genetically modified
cells were grown in puromycin (1 mg/ml) to maintain the presence
of the transfer vector.
For lentiviral knockdown in mouse hippocampal neurons, we
used a variant of the pLKO.1-puro lentiviral vector (Sigma), in
which the puroR marker was replaced by an eGFP-WPRE-
encoding fragment (introduced between the Acc65 and BamHI
sites). The sense targeting sequence for mouse Ptpn12 was
GCCCTAAAGGTTGATGATGTA and for the non-targeting
control CAACAAGATGAAGAGCACCAA (Sigma TRC1.5
clone SHC002). Viral supernatant was concentrated (100-fold)
by ultracentrifugation at 80,0006g for 2 h at 4uC in conical tubes
using the SW32 Ti rotor (Beckman). The viral pellet was
resuspended in PBS, aliquoted and stored at 280uC. Titer was
estimated by infecting 293T cells with virus dilutions and
quantification of GFP positive cells by flow cytometry (BD
FACSCalibur) after 4 days.
Culture, lentiviral transduction, and analysis of primary
hippocampal neurons. Animal work was conducted in accor-
dance with relevant national and international guidelines,
specifically as issued by the French Ministry of Agriculture, and
approved by Direction De´partementale des Services Ve´te´rinaires de Paris
(Paris departmental directorate of veterinary services). Animals
were sacrificed by cervical dislocation. E16 fetal mouse brains
were dissected, dissociated and cultured largely as described in
[104]. Briefly, after trypsin and DNAse treatment, 1.56105
primary hippocampal neurons were seeded in 12-well plates pre-
coated with poly-D-lysine (Sigma) in neurobasal medium supple-
mented with 1X B27 (Life Technologies), of which half was
replaced every 2–3 days. Lentiviral transduction was performed
60–90 min after plating at a multiplicity of 5. After 5 days in
culture, infected neurons were stimulated with BDNF as indicated
for 5 min before lysis.
Cell lysates and immunoprecipitation. SH-SY5Y cells
were seeded in 24-well plates (NUNC) in RA medium and
transfected with siRNAs after 3 days. 48 h post-transfection, cells
were changed into serum-free MEM medium with 10 ng/ml
BDNF and left to differentiate as indicated. Cells were washed
twice in PBS and lysed in a lysis buffer containing 62.5 mM Tris-
HCl pH 6.8, 2% SDS, 10% glycerol, 1 mM DTT, 0.025%
bromophenol blue, 1 mM Na3VO4, 50 mM NaF, 10 mg/ml
leupeptin, 10 mg/ml aprotinin and 1 mM PMSF. Lysates were
boiled for 5 min and equal volumes used directly for western
blotting. TrkB-SH-SY5Y cells were grown and stimulated as
described, washed twice with cold PBS, and lysed on ice in RIPA
buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 1% Triton-X-100,
1% sodium deoxycholate, 0.1% SDS, 1 mM EGTA, 1 mM
Na3VO4, 50 mM NaF, 10 mg/ml leupeptin, 10 mg/ml aprotinin,
and 1 mM phenylmethylsulfonyl fluoride (PMSF)). Lysates were
cleared by centrifugation at 12,000 rpm for 20 min at 4uC and
protein concentration quantified with the bicinchoninic acid
protein assay (Pierce). Immunoprecipitation of Trk receptors was
carried out with magnetic dynabeads (Invitrogen) using 500 mg
protein and an anti-Trk antibody (sc-11, Santa Cruz Biotechnol-
ogy). C57BL/6 mice were bred and kept at conventional animal
facilities at the University of Copenhagen. Lysates from whole
brain homogenates were prepared using TM buffer (Chemicon).
Cerebellar granule neurons prepared as previously described [105]
were cultured for 3 days in vitro and lysed in RIPA buffer.
Hippocampal neurons were lysed in 50 mM Hepes pH 7.5,
150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 10% Glycerol, 1%
Triton X-100, 1 mM Na3VO4, 10 mM NaF, 4% Protease
Inhibitor Cocktail (Roche), and 1 mM PMSF.
Western blotting. Equal amounts of protein were resolved
by standard SDS-polyacrylamide gel electrophoresis and trans-
ferred to Immobilon PVDF membrane (Millipore). Membranes
were blocked in PBS-Tween (0.1%) and 5% non-fat dry milk
powder for 1 h at room temperature and incubated overnight at
4uC in primary antibodies: anti-p130cas (#610271), anti-FAK
(#610088) and anti-TRKB (#610101) (all from BD Transduction
Laboratories), anti-TRK (C-14) (#sc-11 from Santa Cruz
Biotechnology, INC.), anti-GAP43 (#NB300-143 from Novus
Biologicals), anti-GAPDH (#G8795), anti-Vinculin (#V9131) and
anti-a-Tubulin (#T9026) (all from Sigma), anti-PTPN12 (a gift
from Dr. M. Tremblay, Department of Medicine, Division of
Experimental Medicine, McGill University, Montreal, Canada),
anti-phosphoTrkB (Y816) (a gift from Dr. M. Chao, Skirball
Institute, New York University School of Medicine), anti-p-44/42
MAPK (ERK1/2) (#9101) and anti-p-AKT (Ser 473) (#4051)
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(both from Cell Signaling), anti-ROCK I (#sc-6055 from Santa
Cruz Biotechnology) or anti-phosphot-yrosine 4G10 (prepared as
a hybridoma culture supernatant). Blots were subsequently
incubated for 1 h at room temperature with horseradish perox-
idase-conjugated secondary antibodies (Jackson Immunoresearch
Laboratories), and developed with an enhanced chemiluminis-
cence detection system (PerkinElmer Life Sciences or Thermo-
scientific). Band intensities were quantified with ImageJ or Fusion
software. To assay more than one protein on the same membrane,
membranes were incubated in stripping buffer (62.5 mM Tris
pH 6.78, 2% SDS, 100 mM mercaptoethanol) for 45 min at 60uC
before reblotting.
High-throughput neurite outgrowth screen. SH-SY5Y
cells were seeded into twelve 96-well plates (NUNC) in RA
medium and transfected 3 days later with the siRNA library. 48 h
post-transfection, cells were changed into serum-free MEM
medium with 10 ng/ml of BDNF, and left to differentiate for 3
more days. Cells were then fixed in 3.5% paraformaldehyde and
0.5% glutaraldehyde in PBS for 20 min at 4uC, permeabilized
with 0.2% Triton-X-100, and stained with an antibody to b-III-
tubulin (Sigma T6880; 1:300) overnight at 4uC in 3% BSA in PBS.
The next day an Alexa594-conjugated goat-anti-mouse antibody
(Molecular Probes; 1:400) containing Hoechst 33342 (Molecular
Probes, 0.5 mg/ml) was applied for 1 h at room temperature. After
washing cells were left in PBS. Plating of cells and medium
changes were performed manually, while transfection, fixation and
staining of cells were performed automatically using a Hamilton
Microlab STAR Liquid Handling Station. The screen was
performed three times using different passages of the SH-SY5Y
cell line.
siRNA library. A library targeting 254 phosphatases and
various controls (including siRNAs targeting TrkB (NTRK2), as
well as negative controls) was custom-designed, based on
comprehensive literature and database mining. Three siRNAs/
gene were designed by and ordered from Ambion. The gene list
and siRNA sequences used are available upon request. The library
was delivered in 36384-well plates and dissolved to a concentra-
tion of 1.2 mM, and was at the time of transfection of siRNAs
automatically distributed out into 12 96-well plates. As controls for
positive and negative modulation of neurite outgrowth, function-
ally validated siRNAs targeting TrkB or ROCK1 were spotted
manually into the 384-well plates (resulting in their presence twice
in each 96-well plate). For validation experiments, siRNAs
including controls were purchased from Sigma.
Automated image analysis for neurite outgrowth. 15
images/well were acquired using an IN Cell Analyzer 1000
automated high-throughput microscope (GE Healthcare) installed
with a Nikon 206 objective, and the images were automatically
analyzed using an algorithm designed using the IN Cell Developer
software (GE Healthcare). Briefly, nuclei were first segmented and
counted using the Hoechst channel. Then a segmentation mask
was superimposed over cell bodies and their associated neurites
using the b–III-tubulin channel. A representative cell body size
was then approximated using random images from control wells
and subsequently subtracted from the ‘cell body/neurite’ bitmap
to generate a ‘neurite’ bitmap. Neurite length was determined
using the ‘fiber length’ parameter of the IN Cell Developer
software, which measures the total length within a single fibrous
shape. Finally, neurite length/cell was calculated by dividing the
total measured neurite length by the number of nuclei in each well.
Typically at least 800 cells/well were counted. Neurite-like
morphology of TrkB-SH-SY5Y cells was analyzed automatically
with the IN Cell Analyzer 1000 workstation 3.5 software package
using the form factor profile, where 1 is a completely round cell
and cells with a form factor .3.5 had various long protrusions
from the cell morphologically resembling neurites. Cells with a
form factor .3.5 were scored as having neurite-like protrusions.
Data normalization. Activity (neurite length per cell) was
first normalised to the plate median and further to the median row
activity of the particular screen to control for edge effects observed
across the rows. Following normalisation the average activity for
each sequence-specific siRNA over the three screens was
calculated and used for subsequent statistical analysis. Due to
the three-fold redundancy of the siRNA library, three activity
values per gene were used for the statistical analysis.
Statistical analysis. Statistical analysis was carried out using
redundant siRNA activity (RSA) analysis as described in [55]. Two
different analyses were carried out: one for identification of
positive regulators and one for identification of negative regulators
(see Materials and Methods Document S1 for details).
Supporting Information
Figure S1 Effect of RA/BDNF differentiation of SH-
SY5Y cells on GAP43 protein levels. Non-differentiated (ND)
SH-SY5Y cells, cells treated with RA for 5 or 8 days, and cells
treated for 5 days with RA followed by 3 days with BDNF (50 ng/
ml) were evaluated for GAP43 protein levels by Western blotting
using GAPDH as a reference. Densitometric quantification of
GAP43 compared to GAPDH levels is shown as mean and S.E.M.
of three independent experiments with GAP43 and GAPDH
values normalized to the level of the control without RA and
BDNF (5d ND). Statistical analysis was performed using Student’s
paired t-test (*: p#0.05).
(TIF)
Figure S2 Transfection efficiency in RA/BDNF differ-
entiated SH-SY5Y cells. A) Cells were plated, treated and
transfected with siGLO siRNA according to the assay outline in
Figure 2A. Transfection efficiency was evaluated by flow
cytometry analysis 24 h post-transfection. Red and blue lines
represent non-transfected and transfected cells, respectively. B)
Lipofectamine was left out of the transfection reaction to verify
that the high transfection efficiency observed was not caused by
siGLO siRNA sticking to the surface of the transfected cells (same
line coloring as in A).
(TIF)
Figure S3 Test of scrambled siRNAs at different BDNF
concentrations. The neurite outgrowth assay was performed as
described in Figure 2A with six different scrambled (SCR) siRNAs.
Control refers to non-transfected cells, while mock refers to cells
transfected without siRNA. Transfections were tested at 0, 10 and
50 ng/ml BDNF. Data are shown as mean and S.E.M. of four
replicates.
(TIF)
Figure S4 siRNA-mediated knockdown efficiency in
RA/BDNF differentiated SH-SH5Y cells. Four hits random-
ly selected among the ones chosen for validation were evaluated
for siRNA-mediated knockdown efficiency. Cells were plated,
treated and transfected as described in Figure 2A. 72 h post-
transfection (and 24 h after addition of 10 ng/ml BDNF), mRNA
expression was analyzed by qPCR. Data are normalized to
HRPT1 expression levels and shown relative to the UNC1
scrambled control, as mean and S.E.M. of triplicates. The
experiment is representative of two independent experiments.
(TIF)
Figure S5 Validation of hits at different BDNF concen-
trations. Hits selected for validation were tested for their effect in
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the absence of BDNF (A and B), or in the presence of a
saturating BDNF concentration (50 ng/ml) (C and D), as
opposed to 10 ng/ml BDNF used in the screen and the primary
validation. UNC1 is the scrambled siRNA control while
ROCK1 or TrkB targeting siRNAs served as biological controls.
A and C: 11 negative regulators; B and D: 4 positive regulators.
Red and green indicate negative and positive regulators,
respectively, and filled and open bars represent validated and
non-validated hits, respectively. Data are shown as mean and
S.E.M. of triplicates (*: p#0.05; **: p#0.01; and ***: p#0.001;
using one-way ANOVA followed by Dunnett’s multiple com-
parison test with UNC1 as reference).
(TIF)
Figure S6 Neurite outgrowth of TrkB-SH-SY5Y cells in
response to BDNF. A) TrkB expression in different cells and
tissue. Lysates from SH-SY5Y cells differentiated for 5 days with
RA, non-treated TrkB-SH-SY5Y cells, mouse whole brain
homogenate and mouse cerebellar granule neurons (CGNs)
cultured for 3 days in vitro were evaluated for TrkB expression
using western blotting. Vinculin was used as reference. B) TrkB-
SH-SY5Y cells were plated for 24 h, followed by 3 days in the
absence or presence of 50 ng/ml BDNF. Phase contrast pictures
were taken at 206 magnification. Scale bar = 20 mm. C) Cells
treated as in B) were evaluated for GAP43 expression using
western blotting with GAPDH as reference.
(TIF)
Table S1 RSA analysis of negative regulators of BDNF-
TrkB mediated neurite outgrowth.
(XLSX)
Table S2 RSA analysis of positive regulators of BDNF-
TrkB mediated neurite outgrowth.
(XLSX)
Document S1 Supporting Materials and Methods.
(DOCX)
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